共 50 条
- [21] The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinomaSCIENTIFIC REPORTS, 2021, 11 (01)Kanzaki, HiroakiChiba, TetsuhiroAo, JunjieKoroki, KeisukeKanayama, KengoMaruta, SusumuMaeda, TakahiroKusakabe, YukoKobayashi, KazufumiKanogawa, NaoyaKiyono, SoichiroNakamura, MasatoKondo, TakayukiSaito, TomokoNakagawa, RyoOgasawara, SadahisaSuzuki, EiichiroOoka, YoshihikoMuroyama, RyosukeNakamoto, ShingoYasui, ShinTawada, AkinobuArai, MakotoKanda, TatsuoMaruyama, HitoshiMimura, NaoyaKato, JunZen, YohOhtsuka, MasayukiIwama, AtsushiKato, Naoya
- [22] H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular CarcinomaCANCER RESEARCH, 2017, 77 (24) : 6999 - 7013Joshi, Jaya JulieCoffey, HeatherCorcoran, ErikTsai, JenniferHuang, Chia-LingIchikawa, KanaPrajapati, SudeepHao, Ming-HongBailey, SuzannaWu, JeremyRimkunas, VictoriaKarr, CraigSubramanian, VanithaKumar, PavanMacKenzie, CrystalHurley, RaeleneSatoh, TakashiYu, KunPark, EuniceRioux, NathalieKim, AmyLai, Weidong G.Yu, LihuaZhu, PingBuonamici, SilviaLarsen, NicholasFekkes, PeterWang, JohnWarmuth, MarkusReynolds, Dominic J.Smith, Peter G.Selvaraj, Anand
- [23] The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinomaScientific Reports, 11Hiroaki KanzakiTetsuhiro ChibaJunjie AoKeisuke KorokiKengo KanayamaSusumu MarutaTakahiro MaedaYuko KusakabeKazufumi KobayashiNaoya KanogawaSoichiro KiyonoMasato NakamuraTakayuki KondoTomoko SaitoRyo NakagawaSadahisa OgasawaraEiichiro SuzukiYoshihiko OokaRyosuke MuroyamaShingo NakamotoShin YasuiAkinobu TawadaMakoto AraiTatsuo KandaHitoshi MaruyamaNaoya MimuraJun KatoYoh ZenMasayuki OhtsukaAtsushi IwamaNaoya Kato
- [24] FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular CancerMOLECULAR CANCER THERAPEUTICS, 2019, 18 (12) : 2194 - 2206Weiss, AndreasAdler, FlaviaBuhles, AlexandraStamm, ChristelleFairhurst, Robin A.Kiffe, MichaelSterker, DarioCenteleghe, MarioWartmann, MarkusKinyamu-Akunda, JacquelineSchadt, Heiko S.Couttet, PhilippeWolf, ArminWang, YouzhenBarzaghi-Rinaudo, PatriziaMurakami, MasatoKauffmann, AudreyKnoepfel, ThomasBuschmann, NicoleLeblanc, CatherineMah, RobertFuret, PascalBlank, JuttaHofmann, FrancescoSellers, William R.Porta, Diana Graus
- [25] FGF19-Based Mini Probe Targeting FGFR4 for Diagnosis and Surgical Navigation of Hepatocellular CarcinomaJOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (05) : 3764 - 3777Cai, JiaxianLian, ChenLu, ZeyuShang, QianWang, LiHan, ZhihaoGu, Yueqing
- [26] FGF19-MEDIATED ELF4 OVEREXPRESSION PROMOTES COLORECTAL CANCER METASTASIS THROUGH FGFR4 AND SRCGASTROENTEROLOGY, 2023, 164 (06) : S174 - S174Xia, Limin
- [28] Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancerEUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 214Chen, XiaoluLiu, YananZhang, LitingChen, DaoxingDong, ZhaojunZhao, ChengguangLiu, ZhiguoXia, QinqinWu, JianzhangChen, YonghengZheng, XiaohuiCai, Yuepiao
- [29] FGF19-mediated ELF4 overexpression promotes colorectal cancer metastasis through transactivating FGFR4 and SRCTHERANOSTICS, 2023, 13 (04): : 1401 - 1418Chen, XilangChen, JieFeng, WeiboHuang, WenjieWang, GuodongSun, MengyuLuo, XiangyuanWang, YijunNie, YongzhanFan, DaimingWu, KaichunXia, Limin
- [30] NVP-FGF401, a first-in-class highly selective and potent FGFR4 inhibitor for the treatment of HCCCANCER RESEARCH, 2017, 77Porta, Diana GrausWeiss, AndreasFairhurst, Robin A.Wartmann, MarkusStamm, ChristelleReimann, FlaviaBuhles, AlexandraKinyamu-Akunda, JaquelineSterker, DarioMurakami, MasatoWang, YouzhenEngelman, JeffreyHofmann, FrancescoSellers, William R.